Monkey pox mRNA immunogen composition capable of rapidly and efficiently enhancing immune response and application of monkey pox mRNA immunogen composition
By encoding multiple protective epitopes and IL-15 in mRNA vaccines, a multivalent fusion immunogen composition was constructed, which solved the problems of severe side effects and low immunity of existing vaccines, and achieved high efficiency against monkeypox virus Prevention and protection.
Patent Information
- Application Number
- CN202411249801.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
The existing monkeypox vaccine has severe side effects and low immunity, which cannot effectively induce an immune response, especially among HIV-infected patients, and lacks fast and efficient preventive measures.
Develop an mRNA vaccine to build a multivalent fusion immunogen composition by encoding multiple protective epitopes and immune enhancement factor IL-15 in monkeypox virus to achieve enhanced immune response and independent expression, suitable for the general population and low immunity .
The efficient neutralizing antibody induction and T cell response to monkeypox virus and vaccinia virus has been achieved, providing stronger protection efficiency, and providing safer preventive measures for different populations, especially in HIV-infected patients.
Smart Images

Figure CN119055765A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and pharmaceutical industry, and relates to an mRNA vaccine immunogen composition related to the manufacture of genetically engineered drugs and vaccines and its application, and in particular to a monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response and its application. Background Art
[0002] Monkeypox is a zoonotic infectious disease caused by the monkeypox virus (MPXV). Its typical clinical manifestations include fever, headache, swollen lymph nodes and muscle pain, accompanied by rash after fever, etc. MPXV is a double-stranded DNA virus with two infectious virus particle forms: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV). It can be transmitted among people through direct contact (sexual contact or skin contact) and respiratory droplets.
[0003] Vaccination is the most effective means of preventing and controlling infectious diseases. At present, no monkeypox-specific vaccine has been approved in China. There are two main smallpox vaccines used to prevent monkeypox, including the emergency-approved attenuated vaccine such as ACAM2000, which can cause serious side effects including myocarditis and pericarditis; and JYNNEOS (MVA-BN; also known as IMVANEX, IMVAMUNE) vaccination will cause mild side effects such as redness and swelling at the injection site and allergies, and breakthrough infection events may occur after vaccination due to its low immunogenicity. Against the background of declining global smallpox immunity, there is an urgent need to develop a safer, more effective monkeypox virus vaccine that can quickly induce the body's response and has a higher protection efficiency to combat the potential increase in the prevalence of monkeypox.
[0004] All the vaccines currently under development are based on the key epitopes of the monkeypox virus or its highly homologous vaccinia virus IMV and EEV to develop monkeypox vaccines to induce effective neutralizing antibodies to prevent the virus from entering host cells. According to the latest epidemiological survey report of the WHO, about 85% of monkeypox patients are men who have sex with men, and most of them are also infected with HIV. Immunodeficiency may increase the risk of infection and the risk of severe illness and death. Therefore, it is crucial to develop more effective and faster vaccines to induce immune responses for people with immunodeficiency or low immune function such as HIV.
[0005] Interleukin 15 (IL-15), a member of the γ-chain receptor cytokine family, is widely expressed in a variety of cell types, such as monocytes, macrophages, and dendritic cells. It is a regulatory factor that connects the innate immune system and the adaptive immune system. It plays a vital role in the development, homeostasis, and function of T cells, NK cells, and NK-T cells, and is an immune-enhancing cytokine. In addition, related studies have also shown that IL-15 treatment can compensate for the metabolic defects of NK cells in HIV-1 infection.
[0006] In order to cope with the current epidemic history of monkeypox virus combined with HIV infection and the possibility of further widespread spread among the population, it is urgently necessary to develop a new type of monkeypox mRNA vaccine candidate that can enhance the immune response. Multiple protective epitopes of MPXV can be encoded by the same mRNA molecule, which can be used for vaccination of the general population and for vaccination of specific populations such as those with low immunity, thereby providing safety protection for the surrounding population, which is an urgent problem to be solved by the present invention. Summary of the invention
[0007] In view of this, the purpose of the present invention is to provide an anti-orthopoxvirus mRNA vaccine immunogen composition that can fuse and express the protective antigen protein of monkeypox virus and its homologous protein, and its application in the prevention and treatment of orthopoxvirus infections such as monkeypox virus and vaccinia virus. A monkeypox mRNA vaccine is prepared by constructing an immune-enhancing multivalent fusion immunogen composition, and one injection can effectively induce the body's immune response.
[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0009] The present invention provides a monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response, wherein the composition comprises at least one antigenic peptide or structural protein and an immune enhancing factor IL-15; the antigenic peptide or structural protein is selected from: (1) the amino acid sequence of the full length or a portion of the monkeypox virus A35R protein, or an amino acid sequence having at least 80% to 99% (including 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity thereto and having the same or substantially the same immunogenicity thereto; (2) the amino acid sequence of the full length or a portion of the monkeypox virus M1R protein, or an amino acid sequence having at least 80% to 99% (including 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity thereto and having the same or substantially the same immunogenicity thereto; (3) the amino acid sequence of the whole length or a part of the monkeypox virus A29L protein, or an amino acid sequence that has at least 80% to 99% (including 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity thereto and has the same or substantially the same immunogenicity thereto; the immune enhancing factor is selected from the amino acid sequence of the whole length or a part of the cytokine IL-15 of the gamma chain receptor cytokine family, or an amino acid sequence that has at least 80% to 99% (including 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity thereto and has the same or substantially the same immunogenicity thereto; different candidate immunogenic molecules are arranged by appropriate linker sequences.
[0010] Furthermore, the antigenic peptide or structural protein is selected from: (1) the amino acid sequence shown in SEQ ID NO: 1, (2) the amino acid sequence shown in SEQ ID NO: 2, (3) the amino acid sequence shown in SEQ ID NO: 3; the antigenic peptide or structural protein comprises a combination of two or more, and the two or more antigenic peptides or structural proteins are expressed separately or fused. Preferably, the antigenic peptide or structural protein is expressed fused.
[0011] Furthermore, the immune enhancing factor is selected from the amino acid sequence shown in SEQ ID NO:4.
[0012] Furthermore, in the composition, the linker sequence is mainly derived from the sequence of the self-cleaving peptide, including: linker 1 is a sequence derived from Porcine teschovirus P2A; linker 2 is a sequence derived from Thosea asigna virus T2A; linker 3 is a sequence derived from Foot-and-mouthdisease virus F2A; the order between different linker sequences can be arbitrarily front or back.
[0013] Furthermore, in the linker sequence, linker 1 is the amino acid sequence ATNFSLLKQAGDVEENPGP as shown in SEQ ID NO:5, linker 2 is the amino acid sequence EGRGSLLTCGDVEENPGP as shown in SEQ ID NO:6, and linker 3 is the amino acid sequence GSGVKQTLNFDLLKLAGDVESNPGP as shown in SEQ ID NO:7.
[0014] Furthermore, the composition is a single cistron sequence arranged in series with a linker, which can be loaded into the same mRNA expression vector, thereby achieving translation from the same transcript.
[0015] Furthermore, in order to achieve efficient membrane display of each antigenic peptide or structural protein, the composition replaces its own signal peptide with the secretory signal peptide tPA2 at its N-terminus, and further adds a Kozak sequence before the start codon to enhance expression; the Kozak sequence is shown in SEQ ID NO:12; the amino acid sequence of the secretory signal peptide tPA2 is shown in SEQ ID NO:13; the amino acid sequence of the final monkeypox virus fusion protein candidate immunogen 1 is shown in SEQ ID NO:14 (abbreviated as AMA), and the amino acid sequence of the monkeypox virus fusion protein candidate immunogen 2 is shown in SEQ ID NO:15 (abbreviated as MAA); the amino acid sequence of the immune-enhancing immunogen 1 is shown in SEQ ID NO:16 (abbreviated as AMA-IL-15), and the amino acid sequence of the immune-enhancing immunogen 2 is shown in SEQ ID NO:17 (abbreviated as MAA-IL-15).
[0016] Furthermore, the composition, whose nucleic acid sequence is optimized for codons and RNA secondary structure, includes: the full-length DNA sequence of the antigenic peptide or structural protein as shown in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or a sequence having at least 80% to 99% (including 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) homology with the nucleic acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20; encoding monkeypox virus fusion protein candidate immunogen 1 and monkeypox virus fusion protein candidate immunogen 2 (abbreviated as AMA or MAA) with codon optimization and RNA secondary structure optimization, and the optimized nucleic acid sequences are shown in SEQ ID NO: 21 and SEQ ID NO: 22, respectively; encoding a cytokine IL-15 antigen sequence with codon optimization and RNA secondary structure optimization, and its codon-optimized nucleic acid sequence is shown in SEQ ID NO:23; the codon-optimized and RNA secondary structure-optimized immune-enhancing immunogens 1 and 2 (abbreviated as AMA-IL-15 and MAA-IL-15), whose codon-optimized nucleic acid sequences are shown in SEQ ID NO:24 and SEQ ID NO:25, respectively; the codon-optimized fusion protein immunogen 1, fusion protein immunogen 2 and immune-enhancing immunogen composition 1 and immune-enhancing immunogen composition 2 loaded into the same mRNA vector, whose optimized DNA template sequences that can be used for mRNA preparations are shown in SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29, respectively.
[0017] The present invention also provides an application of the above-mentioned monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response, wherein the composition is used to prepare an immune-enhancing monkeypox mRNA vaccine; the prepared vaccine comprises one or more pharmaceutically acceptable carriers or excipients of the monkeypox mRNA immunogen composition, and the carrier or excipient is suitable for oral, intradermal, subcutaneous, intramuscular or intranasal administration.
[0018] Furthermore, the vaccine is a multivalent fusion immune-enhancing monkeypox nucleic acid vaccine, and the administration method includes (including but not limited to) nasal drops and spray administration, subcutaneous injection, intradermal injection and intramuscular injection. Intramuscular injection and subcutaneous injection are preferred, and intramuscular injection is more preferred in terms of the ease of administration.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The present invention provides a monkeypox mRNA immunogen candidate that can enhance immune response, which can encode multiple protective epitope immunogens of MPXV from one mRNA molecule at the same time, realize independent expression of each immunogen, and do not interfere with each other, and enhance the body's immune response by adding secretory cytokines. When used for vaccine preparation, it can be simply, conveniently and quickly prepared, can quickly induce the body to produce an immune response, has high immunogenicity, can induce high-level neutralizing antibodies to monkeypox virus or vaccinia virus with high homology, and can stimulate strong T cell response. It can be used for vaccination of the general population and is also suitable for vaccination of specific populations such as those with low immunity, thereby providing a guarantee for responding to the current epidemic history of monkeypox virus combined with HIV infection and the possibility of further widespread spread among the population. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 To encode the construction of multivalent mixed immunogens.
[0022] Figure 2 Flow cytometry was used to detect the expression of Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA after transfection of HEK293T cells.
[0023] Figure 3 To evaluate the immunogenicity of Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA vaccines in BALB / c mice.
[0024] Figure 4 After vaccination with Mixture, AMA, and AMA-IL-15 mRNA vaccines, the level of T cell response in the spleen of mice was detected.
[0025] Figure 5 Mixture, AMA, AMA-IL-15mRNA vaccine, monkeypox virus challenge with 3E6 PFU of VACV vaccinia virus per mouse as positive control, monkeypox virus and vaccinia virus challenge protection test and results in mice. DETAILED DESCRIPTION
[0026] The specific implementation of the present invention is further described below in conjunction with the accompanying drawings. These drawings are only for illustrating the implementation of the present disclosure, and are not intended to limit the scope of the present disclosure.
[0027] The present invention provides an mRNA composition, which comprises encoding at least one antigenic peptide or structural protein, wherein the antigenic peptide or structural protein is selected from the intracellular mature virion (IMV) and the extracellular enveloped virion (EEV) of the monkeypox virus, including one or more of the M1R protein, A35R protein, A29L protein or their homologous proteins, and the homologous protein has at least 75% identity with the above proteins and has the same or substantially the same immunogenicity as the amino acid sequence protein or its antigenic fragment. The composition is an amino acid sequence arranged in the pattern of "A-Linker 1-B-Linker 2-C-Linker 3-D Secretory Cytokine" through an appropriate linker sequence.
[0028] Specifically, A represents the amino acid sequence of the full length or a portion of the monkeypox virus A35R protein, or an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and has the same or substantially the same immunogenicity thereto, and is further preferably the amino acid sequence shown in SEQ ID NO:1.
[0029] B represents the amino acid sequence of the full length or a portion of the monkeypox virus M1R protein, or an amino acid sequence that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto and has the same or substantially the same immunogenicity thereto, and is further preferably the amino acid sequence shown in SEQ ID NO:2.
[0030] C represents the amino acid sequence of the full length or a portion of the monkeypox virus A29L protein, or an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and has the same or substantially the same immunogenicity thereto, and is further preferably the amino acid sequence shown in SEQ ID NO:3.
[0031] D represents the amino acid sequence of the full length or a portion of the cytokine IL-15 derived from the γ chain receptor cytokine family, or an amino acid sequence that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto and has the same or substantially the same immunogenicity thereto, and is further preferably the amino acid sequence shown in SEQ ID NO:4.
[0032] In order to achieve independent and correct expression of the antigenic peptides or structural proteins derived from A, B, and C, they are connected through different linkers.
[0033] Preferably, the length of the linker is 1-18 amino acids. Linker 1, linker 2 and linker 3 are the same or different, and are mainly derived from 2A self-cleaving peptide sequences, including but not limited to F2A from Foot-and-mouth disease virus, E2A from Equine rhinitis A virus, P2A from Porcine teschovirus, T2A peptide from Thosea asigna virus, or having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity therewith and having the same or substantially the same amino acid sequence therewith.
[0034] Linker 1 is preferably a sequence derived from Porcine teschovirus P2A, i.e., the amino acid sequence ATNFSLLKQAGDVEENPGP as shown in SEQ ID NO:5; Linker 2 is preferably a sequence derived from Thosea asigna virus T2A, i.e., the amino acid sequence EGRGSLLTCGDVEENPGP as shown in SEQ ID NO:6, and Linker 1 and Linker 2 may be in the first or the second order.
[0035] Linker 3 is preferably a sequence derived from the foot-and-mouth disease virus F2A, that is, the amino acid sequence GSGVKQTLNFDLLKLAGDVESNPGP as shown in SEQ ID NO:7.
[0036] The order of A, B, and C can be exchanged for the following sequences: ABC, ACB, CBA, and BCA; more preferably, the candidate immunogen 1 encoding the monkeypox virus fusion protein is arranged in the order of ABC and / or the candidate immunogen 2 encoding the fusion protein is arranged in the order of BAC, including the amino acid sequences shown in SEQ ID NO:8 and SEQ ID NO:9; the immune-enhancing immunogens 1 and 2 are the amino acid sequences after the fusion protein candidate immunogens are connected to D, as shown in SEQ ID NO:10 and SEQ ID NO:11, respectively.
[0037] The immunogen and secretory cytokine induced by the present invention for encoding multiple protective epitopes of MPXV can be loaded into an mRNA expression vector.
[0038] Preferably, the mRNA expression vector further includes basic elements required for transcription from the 5' end to the 3' end, specifically T7 promoter region, 5' non-translated region, coding sequence, 3' non-coding region and polyadenylic acid tail (polyA) sequence. The coding sequence includes but is not limited to MPXV multiple protective epitope immunogens that can induce neutralizing antibodies and secretory cytokine immunogen compositions that enhance immune response.
[0039] In order to achieve efficient membrane display of each neutralizing epitope, the N-terminus of the multiple neutralizing epitope proteins of the monkeypox virus is replaced with the secretory signal peptide tPA2 to replace its own signal peptide, and the Kozak sequence is further added before the start codon to enhance expression, and the Kozak sequence is shown in SEQ ID NO: 12; the amino acid sequence of the secretory signal peptide tPA2 is shown in SEQ ID NO: 13; the final amino acid sequence of the candidate immunogen 1 of the monkeypox virus fusion protein is shown in SEQ ID NO: 14 (abbreviated as AMA), and the amino acid sequence of the candidate immunogen 2 of the monkeypox virus fusion protein is shown in SEQ ID NO: 15 (abbreviated as MAA); the amino acid sequence of the immune-enhancing immunogen 1 is shown in SEQ ID NO: 16 (abbreviated as AMA-IL-15), and the amino acid sequence of the immune-enhancing immunogen 2 is shown in SEQ ID NO: 17 (abbreviated as MAA-IL-15).
[0040] More preferably, the immunogenic composition is used to prepare an immune-enhancing monkeypox mRNA vaccine.
[0041] The mRNA vaccine includes:
[0042] a) encoding a codon-optimized M1R antigen sequence, wherein the codon-optimized nucleic acid sequence is shown in SEQ ID NO: 18.
[0043] b) encoding a codon-optimized A35R antigen sequence, the codon-optimized nucleic acid sequence is shown in SEQ ID NO: 19.
[0044] c) encoding a codon-optimized A29L antigen sequence, the codon-optimized nucleic acid sequence is shown in SEQ ID NO: 20.
[0045] d) encoding a codon-optimized candidate immunogen 1 encoding monkeypox virus fusion protein, referred to as AMA, or a candidate immunogen 2 encoding fusion protein, referred to as (MAA), the nucleic acid sequences after codon optimization are shown in SEQ ID NO: 21 and SEQ ID NO: 22, respectively.
[0046] e) encoding a codon-optimized cytokine IL-15 antigen sequence, wherein the codon-optimized nucleic acid sequence is shown in SEQ ID NO: 23.
[0047] f) The codon-optimized encoding immune-enhancing immunogen 1 is referred to as AMA-IL-15, and the codon-optimized encoding immune-enhancing immunogen 2 is referred to as MAA-IL-15. The nucleic acid sequences after codon optimization are shown in SEQ ID NO: 24 and SEQ ID NO: 25, respectively.
[0048] g) encoding a codon-optimized fusion protein immunogen and an immune-enhancing immunogen composition loaded into the same mRNA vector, which can be used to prepare mRNA preparations after codon optimization. The DNA template sequence encoding the monkeypox virus fusion protein candidate immunogen 1 is as shown in SEQ ID NO: 26, the DNA template sequence encoding the monkeypox virus fusion protein candidate immunogen 2 is as shown in SEQ ID NO: 27, the DNA template sequence encoding the monkeypox virus fusion protein immune-enhancing immunogen composition 1 is as shown in SEQ ID NO: 28, and the DNA template sequence encoding the monkeypox virus fusion protein immune-enhancing immunogen composition 2 is as shown in SEQ ID NO: 29.
[0049] When the immunogen composition is transcribed to prepare the corresponding mRNA, part or all of the uracil and / or cytosine nucleosides can be replaced; its characteristics include using the following substances to replace at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the uracil nucleosides in the mRNA.
[0050] The substance replacing uridine nucleoside is selected from at least one of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-T-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine or 5-methoxyuridine and 2'-O-methyluridine, preferably pseudouridine or N1-methylpseudouridine or N1-ethylpseudouridine, and more preferably N1-methylpseudouridine.
[0051] The present invention also provides a preparation, which includes the mRNA vaccine prepared by encoding multiple protective epitopes of MPXV, the mRNA vaccine encoding the cytokine IL-15, and / or the mRNA vaccine prepared by the immune-enhancing multivalent fusion immunogen composition. The preparation also includes a vector for delivering the mRNA vaccine for preventing and / or treating infection with monkeypox virus or its highly homologous vaccinia virus.
[0052] The carrier includes cationic liposomes, polymers, proteins or lipid nanoparticles, preferably cationic liposomes and cationic lipid nanoparticles, more preferably cationic lipid nanoparticles. The preparation can be prepared by mixing the cationic lipid nanoparticles with the mRNA vaccine.
[0053] The administration methods of the multivalent fusion immune-enhancing monkeypox nucleic acid vaccine include, but are not limited to, intramuscular injection, nasal drops and spray administration, subcutaneous injection, intradermal injection and intramuscular injection, preferably intramuscular injection and subcutaneous injection, and further more preferably intramuscular injection in terms of the ease of administration.
[0054] The nucleic acid and amino acid sequences involved in the present invention are as follows:
[0055] SEQ ID NO: 1, the amino acid sequence derived from part 59L-181T of the monkeypox virus A35R protein:
[0056] 5'
[0057] -LNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSC YILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITK TTSDYQDSDVSQEVRKYFCT-3'
[0058] SEQ ID NO: 2, the amino acid sequence derived from the monkeypox virus M1R protein:
[0059] 5'-MGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNK LKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQN-3'
[0060] SEQ ID NO: 3, the amino acid sequence derived from monkeypox virus A29L protein:
[0061] 5'-MDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLT NLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTG RHPYE-3'
[0062] SEQ ID NO: 4, i.e., the amino acid sequence derived from the cytokine IL-15 from the gamma chain receptor cytokine family:
[0063] 5'-MKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS-3'
[0064] SEQ ID NO: 5, the amino acid sequence derived from Porcine teschovirus P2A:
[0065] 5'-ATNFSLLKQAGDVEENPGP-3'
[0066] SEQ ID NO: 6, the amino acid sequence derived from Thosea asigna virus T2A:
[0067] 5'-EGRGSLLTCGDVEENPGP-3'
[0068] SEQ ID NO: 7, the amino acid sequence of Foot-and-mouth disease virus F2A:
[0069] 5'-GSGVKQTLNFDLLKLAGDVESNPGP-3'
[0070] SEQ ID NO: 8, the amino acid sequence encoding the monkeypox virus fusion protein candidate immunogen 1:
[0071] 5’-LNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTGSGATNFSLLKQAGDVEENPGPMGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQNGSGEGRGSLLTCGDVEENPGPMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYE-3’
[0072] SEQ ID NO:9, the amino acid sequence encoding the candidate immunogen 2 of the monkeypox virus fusion protein:
[0073] 5'--3'
[0074] SEQ ID NO: 10, i.e., the immune-enhancing immunogen 1 is the amino acid sequence of the fusion protein candidate immunogen connected to D:
[0075] 5’-LNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTGSGATNFSLLKQAGDVEENPGPMGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQNGSGEGRGSLLTCGDVEENPGPMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYEEGRGSLLTCGDVEENPGPMKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS-3’
[0076] SEQ ID NO:11, namely, the immunopotentiating immunogen 2 is the amino acid sequence after the fusion protein candidate immunogen is linked to D:
[0077] 5’
[0078] -GAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVK -3'
[0079] SEQ ID NO: 12, Kozak sequence:
[0080] 5'-gccacc-3'
[0081] SEQ ID NO: 13, i.e., the amino acid sequence of secretory signal peptide tPA2:
[0082] 5'-MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGAR-3'
[0083] SEQ ID NO: 14, amino acid sequence of candidate immunogen 1 of monkeypox virus fusion protein, i.e. amino acid sequence of AMA construct:
[0084] 5'--3'
[0085] SEQ ID NO: 15, amino acid sequence of candidate immunogen 2 of monkeypox virus fusion protein, i.e. amino acid sequence of MAA construct:
[0086] 5’-MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQNSSGEQKLISEEDLLEGSGEGRGSLLTCGDVEENPGPLNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTGSGEGRGSLLTCGDVEENPGPMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYE-3’
[0087] SEQ ID NO:16, the amino acid sequence of the immunopotentiating immunogen 1, i.e., the amino acid sequence of the AMA-IL-15 construct:
[0088] 5’-MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARLNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTGSGATNFSLLKQAGDVEENPGPMGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQNGSGEGRGSLLTCGDVEENPGPMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYEEGRGSLLTCGDVEENPGPMKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS-3’
[0089] SEQ ID NO:17, the amino acid sequence of the immunopotentiating immunogen 2, i.e., the amino acid sequence of the MAA-IL-15 construct:
[0090] 5’-MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMIIATTDIQNGSGEGRGSLLTCGDVEENPGPLNQCMSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTGSGEGRGSLLTCGDVEENPGPMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYEEGRGSLLTCGDVEENPGPMKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS-3’
[0091] SEQ ID NO:18, the codon-optimized M1R nucleic acid sequence:
[0092] 5’-ATGGGTGCCGCCGCTTCTATCCAGACAACAGTGAATACCCTGAGCGAGAGAATCTCCTCTAAGCTGGAGCAGGAAGCCAACGCCAGCGCTCAGACAAAATGCGACATCGAGATCGGAAACTTTTACATCAGACAGAACCACGGCTGCAACATCACCGTGAAAAACATGTGCTCCGCCGACGCCGACGCCCAGCTGGATGCTGTGCTGTCTGCTGCTACCGAAACCTATAGCGGACTGACCCCTGAGCAGAAGGCTTATGTGCCCGCCATGTTCACCGCCGCTCTGAATATCCAGACCTCTGTGAACACCGTGGTGAGAGATTTTGAGAACTATGTGAAGCAGACCTGCAACAGCAGCGCCGTGGTGGATAATAAGCTGAAAATCCAGAACGTGATTATCGACGAGTGCTACGGAGCCCCTGGCTCACCTACAAACCTGGAGTTCATCAACACCGGAAGCAGCAAGGGCAACTGCGCCATCAAGGCCCTGATGCAGCTGACCACAAAGGCCACCACCCAGATTGCCCCTAGACAGGTGGCTGGCACCGGAGTGCAGTTTTACATGATCGTGATTGGAGTGATCATTCTGGCCGCCCTGTTCATGTACTACGCCAAGCGGATGCTGTTTACCTCCACCAACGACAAGATCAAGCTGATTCTGGCCAACAAGGAGAACGTGCACTGGACAACCTATATGGACACCTTCTTCAGAACCAGCCCCATGATCATCGCCACAACCGACATCCAGAAC-3’
[0093] SEQ ID NO:19, the codon-optimized A35R nucleic acid sequence:
[0094] 5'-CTGAACCAGTGCATGAGCGCCAACAAGGCCGCCATCACCGACAGCGCCGTGGCCGTGGCCGCCGCCAGCTCCACACACCGGAAGGTCGTGTCCAGCACCACCCAGTACGATCACAAGGAGTCCTGCAACGGGCTGTACTACCAGGGCAGCTGCTACATCCTGCACAGCGATTACAAGAGCTTCG AGGATGCCAAGGCCAACTGCGCCGCCGAGAGCAGCACCCTCCCCAACAAGAGCGACGTGCTGACCACATGGCTGATTGATTACGTGGAGGACACCTGGGGCAGCGACGGGAACCCCATTACAAAGACAACCTCCGACTACCAGGATAGCGACGTGTCCCAGGAGGTCCGGAAGTACTTCTGCACA-3'
[0095] SEQ ID NO:20, i.e., the codon-optimized A29L nucleic acid sequence:
[0096] 5'-ATGGATGGGACACTGTTTCCTGGGGACGACGACCTGGCCATCCCCGCCACCGAGTTCTTCAGCACCAAGGCCGCCAAGAACCCAGAGACCAAGAGGGAGGCCATCGTGAAGGCCTACGGGGACGACAACGAGGAGACTCTGAAGCAGCGGCTGACCAACCTGGAG AAGAAGATCACAAACATTACCACAAAGTTCGAGCAGATCGAGAAGTGCTGCAAGCGCAACGATGAGGTCCTGTTCCGGCTGGAGAACCACGCCGAGACACTGAGGGCCGCCATGATTAGCCTGGCCAAGAAGATTGATGTGCAGACAGGCCGGCACCCCTACGAG-3'
[0097] SEQ ID NO: 21, i.e. the codon-optimized nucleic acid sequence encoding the monkeypox virus fusion protein candidate immunogen 1, referred to as AMA:
[0098]
[0099] SEQ ID NO: 22, i.e. the codon-optimized nucleic acid sequence encoding the monkeypox virus fusion protein candidate immunogen 2, referred to as MAA:
[0100] 5'
[0101]
[0102] SEQ ID NO: 23, i.e., the codon-optimized cytokine IL-15 nucleic acid sequence:
[0103] 5'-ATGAAGATCCTGAAGCCTTACATGAGAAACACATCCATCTCTTGTTACCTGTGTTTCCTGCTGAACTCTCATTTTCTGACCGAGGCTGGAATCCATGTGTTCATCCTGGGATGTGTGTCT GTGGGCCTGCCTAAGACAGAGGCCAATTGGATCGATGTGAGATATGATCTGGAGAAGATCGAGAGCCTGATCCAGTCTATCCACATCGATACAACACTGTACACAGATAGCGATTTTCACCCT AGCTGTAAGGTGACAGCTATGAACTGTTTTCTGCTGGAGCTGCAGGTCATCCTGCACGAGTACAGCAACATGACACTGAATGAGACAGTGAGAAACGTGCTGTACCTGGCCAACAGCACCCTG AGCTCTAACAAGAACGTGGCTGAGTCTGGCTGTAAGGAGTGTGAGGAGCTGGAGGAAAAGACCTTCACAGAGTTTCTGCAGAGCTTCATCAGAATCGTGCAGATGTTCATCAACACAAGC-3'
[0104] SEQ ID NO: 24, i.e., the nucleic acid sequence encoding the immune-enhancing immunogen 1, referred to as AMA-IL-15, after codon optimization:
[0105]
[0106] SEQ ID NO: 25, i.e., the nucleic acid sequence encoding the immune-enhancing immunogen 2, referred to as MAA-IL-15, after codon optimization:
[0107]
[0108] SEQ ID NO: 26, i.e., DNA template sequence for preparing mRNA preparation, encoding monkeypox virus fusion protein candidate immunogen 1:
[0109]
[0110] SEQ ID NO: 27, i.e., DNA template sequence for preparing mRNA preparation, encoding monkeypox virus fusion protein candidate immunogen 2:
[0111]
[0112] SEQ ID NO: 28, i.e., a DNA template sequence for preparing an mRNA preparation encoding a monkeypox virus fusion protein immune-enhancing immunogenic composition 1:
[0113]
[0114] SEQ ID NO: 29, i.e., a DNA template sequence for preparing an mRNA preparation encoding a monkeypox virus fusion protein immune-enhancing immunogenic composition 2:
[0115]
[0116] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, rather than to limit the scope of the present invention.
[0117] If no specific techniques or conditions are specified in the examples, they are all conventional methods, carried out according to the techniques or conditions described in the literature in the field, or according to the product instructions. The reagents or instruments used are conventional products that can be purchased through regular channels.
[0118] The materials, methods, animals, etc. involved in each example are described as follows.
[0119] Biosafety and Ethical Statement:
[0120] The mouse breeding and related experiments involved in this patent were all carried out in Shenzhen Third People's Hospital. Conventional immunizations were carried out in relevant laboratories in specific pathogen free (SPF) areas, and virus challenge experiments were carried out in biosafety level 3 laboratories. All experimental operating procedures were approved by the Ethics Committee of Shenzhen Third People's Hospital (approval number: 2024-007), and the experimental process was carried out strictly in accordance with the established procedures.
[0121] Experimental Animals:
[0122] All mice used in the experiment were of specific pathogen free (SPF) grade. BALB / c mice (female, 6-8 weeks old) were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. and were raised in the SPF experimental area of Shenzhen Third People's Hospital. The monkeypox virus real virus challenge experiment was carried out in the animal biosafety level 3 (ABSL3) facility of Shenzhen Third People's Hospital.
[0123] Cells and viruses:
[0124] HEK-293T and Vero E6 cell lines (human embryonic kidney cell 293) were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. The monkeypox virus hMpxV / China / SZ-SZTH42 / 2023 isolate was from the clinical isolate of Shenzhen Third People's Hospital, and the vaccinia virus Tiantan strain TV-752-1 was donated by Fudan University; both monkeypox virus and vaccinia virus were propagated in Vero E6 cells.
[0125] Unless otherwise specified, the reagents, instruments, equipment and methods used in this patent are conventional commercially available reagents, instruments, equipment and methods in this technical field.
[0126] The mRNA preparation, mRNA vaccine preparation, animal immunization scheme, and detection methods involved in the experiments of this patent are shown in the following embodiments.
[0127] Example 1. Construction of multivalent mixed immunogens and multivalent fusion immunogens.
[0128] AMA, MAA, AMA-IL-15, and MAA-IL-15 were constructed according to the following immunogen design method. The construction schematic diagrams are shown in the following figure. Figure 1 shown.
[0129] The figure shows the construction encoding multivalent mixed immunogens, including M1R, A35R, and A29L separate constructs (referred to as Mixture), multivalent fusion immunogen constructs, namely, M1R, A35R, and A29L tandem fusion expression (referred to as AMA, MAA), and immune-enhancing fusion immunogen constructs with the addition of IL-15 cytokine (referred to as AMA-IL-15, MAA-IL-15).
[0130] Design of immunogen:
[0131] The A29L, M1R, and A35R proteins involved in the present invention are selected from the monkeypox virus MPXV-M5312_HM12_Rivers strain that newly broke out in 2022.
[0132] The various multivalent immunogens and fusion immunogens involved in the present invention are constructed as follows:
[0133] 1) Mixture construct (abbreviated as Mixture): A mixed immunogen was constructed using the full-length A35R protein, the extracellular end of the M1R protein, and the full-length A29L protein encoded by the monkeypox virus (the amino acid sequences are shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively).
[0134] 2) A multivalent fusion immunogen construct formed by three proteins in series, including an A35R-M1R-A29L construct (AMA for short), such as the amino acid sequence shown in SEQ ID NO: 14; and an M1R-A35R-A29L construct (MAA for short), such as the amino acid sequence shown in SEQ ID NO: 15.
[0135] 3) An immune-enhancing immunogen construct, comprising adding an IL-15 domain (shown in SEQ ID NO:4) to the A35R-M1R-A29L construct (AMA for short) sequence to obtain an immune-enhancing immunogen construct 1, such as the amino acid sequence shown in SEQ ID NO:16 (AMA-IL-15 for short); adding an IL-15 domain to the M1R-A35R-A29L construct (MAA for short) sequence to obtain an immune-enhancing immunogen construct 2, such as the amino acid sequence shown in SEQ ID NO:17 (MAA-IL-15 for short).
[0136] The corresponding nucleotide sequences of different immunogens AMA, MAA, AMA-IL-15, and MAA-IL-15 were optimized by eukaryotic cell codons, and the codon-optimized nucleic acid sequences were shown in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, and SEQ ID NO:25, respectively; they were synthesized by Shanghai Shenggong Biotechnology Co., Ltd., and the four nucleic acid sequences were inserted into the same expression mRNA vector. The corresponding DNA template sequences used to prepare mRNA are shown in SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively.
[0137] Example 2: After HEK293T cells were transfected with Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA, expression was verified by flow cytometry.
[0138] Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA were prepared according to the following mRNA vaccine preparation method.
[0139] mRNA vaccine preparation:
[0140] The different immunogens AMA, MAA, AMA-IL-15, and MAA-IL-15 expression vectors constructed in the above I were linearized by a single enzyme digestion method, and candidate mRNAs were prepared by in vitro transcription by co-transcription capping. According to the T7 in vitro transcription kit (E131-01A) of the Nearshore, N1-methyl pseudouridine triphosphate (Nanjing Shenji Biological, N1-Me-pUTP, 100mM, NMPUTP001) was used to completely replace uridine triphosphate during in vitro transcription. In addition, the cap analog CAP GAG (3OMe) (Nanjing Shenji Biological, CAP3111) was added to co-transcribe and cap to produce a natural Cap1 structure in one step. The corresponding modified mRNA was synthesized according to the instructions, purified by lithium chloride precipitation, washed 3 times with 75% ethanol, and dried, dissolved in RNAase-free water, and the concentration was determined by Nanodrop. The prepared mRNA molecules were sent to Nohai Life Science Instrument (Shanghai) Co., Ltd. to prepare mRNA liposome nanoparticle vaccines for subsequent mouse experiments.
[0141] Then, Lipofectamine 3000 Reagent transfection reagent was mixed with mRNA molecules respectively and then transfected into HEK293T for verification.
[0142] 12 hours before transfection, HEK293T cells were seeded into 12-well plates at a density of 200,000 cells / well. The culture medium was DMEM complete medium, diluted with Opti-MEM (invitrogen), and 1 μg of mRNA was transfected into each well. A mixture was prepared with Lipofectamine3000 at a mass volume ratio of 1:2, and added dropwise to the well plate. The cells were cultured in an incubator at 37°C for 24 hours, and samples were collected for detection. Flow cytometry was performed for verification. The primary antibodies were M1R, A35R, and A29L specific antibodies, and the secondary antibodies were FITC-coupled fluorescent secondary antibodies.
[0143] The process of flow cytometry validation is as follows.
[0144] Flow cytometry to detect the expression of target protein:
[0145] a) Collect cells in flow cytometry tube and centrifuge at 500 g for 5 min.
[0146] b) Wash once with 0.5 mL staining buffer and centrifuge at 500 g for 5 min. Use a pipette to carefully aspirate the supernatant, taking care not to aspirate the cells at the bottom of the tube.
[0147] c) Prepare fluorescent antibody mix (three antibodies were purchased from Sino Biological, A29L antibody number 40891-M0025, A35R number 40886-T62, M1R antibody number 40889-T62, diluted 1:100), mix the antibody mix, centrifuge for 10 seconds to remove the antibody remaining on the tube wall. Add 50μL / sample to the sample and mix, incubate at 4℃ for 30min. (Antibodies must be taken on ice to extend the service life of the antibodies. Staining system: 1*106, 50μL reaction system, less than 3*105, 20μL reaction system)
[0148] d) After the reaction is completed, add 0.8 mL of staining buffer and wash once, 500g for 5 minutes, and discard the supernatant. Then add mouse anti-rabbit IgG-FITC and goat anti-mouse IgG-FITC antibodies, dilute them at 1:100, incubate at 4°C for 30 minutes, wash the cells, and then resuspend them in staining buffer. Fortessa instrument is used for detection (resuspend in 250 μL) and use flow cytometer for detection.
[0149] Results Figure 2 , The figure shows the expression of Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA after transfection into HEK293T cells, and then detected by flow cytometry.
[0150] like Figure 2 As shown in the figure, all candidate mRNA molecules can be expressed at high levels after transfection into HEK293T cells; among them, the expression rates of M1R, A35R and A29L in the multivalent mixed immunogen Mixture group were 96.3%, 92.3% and 82.3%, respectively, and after transfection with the mRNA of the multivalent fusion immunogen AMA / MAA, the mixed expression rate of these three genes can also be as high as 80%-99%; the expression efficiency of A35R in the multivalent fusion immunogen MAA / MAA-IL-15 group was low, which is speculated to be due to the influence of the secondary structure of A35R. Higher levels of protein expression indicate that the candidate mRNA has good efficacy.
[0151] Example 3. Evaluation of the immunogenicity of Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA vaccines in BALB / c mice.
[0152] The mRNA that was correctly expressed after verification in Example 2 was selected and encapsulated into an mRNA cationic lipid nanoparticle vaccine for animal experimental immune evaluation.
[0153] The specific antibody responses of M1R, A35R and A29L after vaccination of mice were detected according to the following method. To evaluate the speed of protective immunity induced by each mRNA vaccine, serum was collected 10 days after vaccination, and the antibody response levels of different vaccination groups to monkeypox virus and vaccinia virus were analyzed by enzyme-linked immunosorbent assay (ELISA) and spot reduction neutralization assay.
[0154] Animal immunization program:
[0155] The first set of immunization experiments was to evaluate the differences in immunogenicity of Mixture, AMA, MAA, AMA-IL-15, and MAA-IL-15 vaccines in BALB / c mice to compare whether they could induce immune responses quickly;
[0156] The BALB / c mouse model of 6-8 weeks old was used, with 5-6 mice in each group, and intramuscular injection was performed. The multivalent mixed immunogen Mixture group was 2.5μg of each immunogen, with a total mass of 7.5μg; the fusion multivalent immunogen was inoculated with 7.5μg per mouse; the control group was an equal volume of Empty-LNP, with a volume of 100μL. Blood was collected 10 days after inoculation, and the binding ability to M1R, A35R, and A29L proteins was detected by enzyme-linked immunosorbent assay (ELISA); the FRNT method was used to detect the neutralizing antibody levels of the mouse sera in different groups against monkeypox virus and vaccinia virus, and the candidate fusion multivalent immunogen groups were determined for subsequent immune analysis.
[0157] The second group of immunization experiments was to further evaluate the level of T cell response induced by different groups based on the above-determined groups. BALB / c mice were used as the model, with 4 mice in each group. The multivalent mixed immunogen Mixture group was inoculated with 2.5 μg of each immunogen, with a total mass of 7.5 μg; the fusion multivalent immunogen was inoculated with 7.5 μg per mouse; the control group was an equal volume of Empty-LNP, with a volume of 100 μL. The T cell response level in the spleen of mice was detected by ELISpot method 10 days after inoculation.
[0158] The third group of immunization experiments is to evaluate the broad-spectrum protective effect of mRNA vaccines of multivalent mixed immunogens and fused multivalent immunogens against monkeypox virus and vaccinia virus in BALB / c mice. BALB / c mice aged 6-8 weeks were used as the challenge model, and vaccinia virus Tiantan strain TV-752-1 (3E6PFU dose / mouse) was inoculated. The intranasal attack was performed on the 11th day after the first injection. The vaccinia virus dose was 1E6 PFU, and the monkeypox virus dose was 5E5 FFU. The inoculation volume of each virus was 25μL. The weight changes and survival of mice in different groups were continuously observed for 14 days.
[0159] The process of ELISpot detection is as follows.
[0160] Mouse IFN-γ ELISPot assay:
[0161] a) Take out the antibody coating of BD's Elispot mouse kit: dilute the anti-IFN-γ antibody 1:200 with sterile PBS according to the number of wells required for the experiment, and add 100 μL / well to the Elispot plate. (Antibody dilution volume calculation: 110 μL for the number of experimental wells) Incubate overnight at 4°C.
[0162] b) Take out the Elispot plate that has been incubated overnight, discard the liquid in the wells, add 200 μL of R10 to wash once, let stand for 3 minutes, and discard. Add 200 μL of fresh R10 and block at room temperature for 2 hours.
[0163] c) After blocking, discard the culture medium, add 50 μL of stimulator (final concentration of stimulatory protein 10 μg / mL), negative control R10, positive control [PMA (50 ng / mL) + Ionomycin (1 μg / mL)] or other positive stimulators) to each well, then adjust the cell concentration to 4 106 cells / mL, and add 50 μL of cells to each well in sequence. After gently mixing, place in a humidified box and incubate in a carbon dioxide incubator for about 20 hours. The first three steps must be performed in a biosafety cabinet, and the following steps do not need to be performed under sterile conditions. The remaining cells are frozen, 500g, 5min, discard the supernatant, add 2mL of commercial freezing solution, and each sample is divided into 2 tubes.
[0164] d) After the incubation, discard the culture. Wash each well twice with 200 μL of pre-cooled distilled water, and three times with 200 μL of PBST, leaving each well for 3-5 minutes before discarding. Pat the remaining liquid dry on absorbent paper (keep the plate moist during the washing process and do not let it dry).
[0165] e) Dilute the biotin-conjugated detection antibody in antibody diluent (PBS + 10% FBS) at 1:250, add 100 μL / well, and incubate at room temperature for 2 hours. Discard the liquid, add 200 μL PBST to each well and wash 4 times. Discard after 1-2 minutes each time, and pat the remaining liquid dry on absorbent paper.
[0166] f) Dilute Streptavidin-HRP in antibody diluent (PBS + 10% FBS) at 1:100, add 100 μL / well, and incubate at room temperature for 1 hour. Discard the reaction solution, add 200 μL PBST to each well and wash 5 times, usually leave it for 1-2 minutes and then discard it. Finally, add 200 μL / well PBS and wash 3 times, then discard it.
[0167] g) Color development: AEC color development solution should be prepared and used immediately: add 1 drop (about 20 μL) of color development substrate to every 1 mL of color development solution, mix thoroughly, and add 100 μL to each well. React at room temperature and avoid light for 5-60 minutes. Pay attention to the degree of color development. When a clear red dot appears, gently rinse the plate with tap water for 5 minutes to stop the reaction. (If the color development time is short, the positive point will be lighter in color. If the time is too long, a darker background will appear. The positive and negative wells can be used as a reference for judgment). Let the plate dry naturally or blow it dry with a fan; read the data. Place the 96-well plate on the Elispot plate reader to read the positive point.
[0168] The results are shown in Figure 3 .
[0169] The figure shows the immunogenicity evaluation of Mixture, AMA / MAA, and MAA-IL-15 / AMA-IL-15 mRNA vaccines in BALB / c mice:
[0170] The mice used in the experiment were 6-8 week old female BALB / c mice, and the immunogens were different mRNA vaccines. Blood was collected 10 days after the first injection, and the ELISA method was used to detect the titers of specific binding antibodies to different immunogens in the serum of mice in different groups, and the FRNT method was used to detect the titers of neutralizing antibodies to monkeypox virus and vaccinia virus in the serum of mice in different groups. Figure 3 A (M1R specific binding antibody titer), Figure 3 B (A35R specific binding antibody titer), Figure 3 C (A29L specific binding antibody titer), Figure 3 D (monkeypox virus true virus specific neutralizing antibody titer), Figure 3 E (vaccinia virus eukaryotic virus-specific neutralizing antibody titer).
[0171] ns or no mark: indicates no significant difference; * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001; **** indicates p<0.0001.
[0172] like Figure 3 As shown in A-3C, all mRNA vaccine groups induced antibodies against M1R at high and low levels, but the antibodies against A35R and A29L induced by the Mixture group, MAA and MAA-mIL-15 groups were lower than those of the AMA and AMA-IL-15mRNA groups ( Figure 3 B and C). Interestingly, the sera vaccinated with the immune-enhancing multivalent fusion immunogen AMA-mIL-15 showed strong neutralization ability against monkeypox virus and vaccinia virus, reaching 74.8% and 66.4%, respectively, indicating that they have the potential to be effective vaccines ( Figure 3D and E). However, the Mixture group vaccinated group showed only about 50% neutralization against monkeypox virus, and the neutralization effect against vaccinia virus was lower than 50% ( Figure 3 E). The addition of the immunopotentiator IL-15 can increase the levels of specific binding antibodies and neutralizing antibodies to a certain extent. These experimental results show that the multivalent fusion immunogen AMA and AMA-IL-15 mRNA vaccine in the present invention have better immunogenicity and are broad-spectrum.
[0173] Example 4: T cell response levels induced by Mixture, AMA, and AMA-IL-15 mRNA vaccines.
[0174] Further explore the level of T cell response induced by multivalent mixed immunogens and fusion immunogens in animals. Studies have reported that effective virus-specific T cells are essential for virus clearance.
[0175] According to the second group of immunization experiments of the animal immunization scheme in Example 3, BALB / c mice were immunized, with 5 mice in each vaccination group, and 4 mice in each empty vector group as the control group. Ten days after the first injection, the mice were killed, spleen cells were taken, and the spleen cells were stimulated with M1R, A35R and A29L proteins respectively, and the T cell immune response level was detected by ELISpot.
[0176] The process of ELISpot detection was the same as that in Example 3.
[0177] The results are shown in Figure 4 The figure shows 6-8 week old female BALB / c mice vaccinated with Mixture, AMA, and AMA-IL-15 mRNA vaccines. Ten days after one injection, the T cell response level in the mouse spleen was detected by ELISpot.
[0178] Figure 4 A is the representative result of Elispot, Figure 4 B is the T cell response level, the ordinate is the number of cells secreting IFN-γ per million spleen cells, and the abscissa is the immune group; ns or no mark: indicates no significant difference (notsignificant); * indicates p<0.05; ** indicates p<0.01.
[0179] All three mRNA vaccines were able to produce high levels of T cell responses in mice ( Figure 4A); Among them, the T cell response induced by the multivalent immunogen AMA was weaker than that of the multivalent mixed immunogen Mixture group. The T cell response induced by the enhanced multivalent fusion immunogen AMA-mIL-15 was the strongest, with the number of positive cells per million spleen cells GMT reaching 458, while in the control group, it was at a lower level ( Figure 4 B). This further suggests that the addition of the immune enhancer IL-15 may be more effective in responding to monkeypox virus infection.
[0180] Example 5. Evaluation of protection of different groups of mRNA vaccines against monkeypox virus and vaccinia virus in BALB / c mice.
[0181] Given that the multivalent mixed immunogen and fusion immunogen mRNA vaccines in Implementation Cases 3 and 4 can induce good antibody and T cell responses in BALB / c mice, this implementation case further explores the protective effects against monkeypox virus and vaccinia virus in mice.
[0182] According to the third group of immunization experiments in the animal immunization scheme in Example 3, BALB / c mice aged 6-8 weeks were used as the challenge model, and the immunization strategy was as follows: Figure 5 As shown in A. On the 11th day after the first injection, intranasal challenge was performed with a vaccinia virus dose of 1E6 PFU and a monkeypox virus dose of 5E5 FFU in a volume of 25 μL. Body weight changes and mortality were monitored within 14 days after the challenge to detect the protective effects of different groups of vaccines against monkeypox virus and vaccinia virus.
[0183] The results are shown in Figure 5 .
[0184] The picture shows Mixture, AMA, and AMA-IL-15 mRNA vaccines. When the monkeypox virus was challenged, 3E6 PFU of VACV was used as a positive control. Ten days after the first injection, the protection test against monkeypox virus and vaccinia virus was carried out in BALB / c mice:
[0185] Figure 5 A: Vaccination and virus attack process.
[0186] Figure 5 B: Changes in body weight of mice in the Empty-LNP group and the vaccine group after monkeypox virus challenge.
[0187] Figure 5 C: Survival rate of mice in the Empty-LNP group and the vaccine group after monkeypox virus challenge.
[0188] Figure 5 D: Changes in body weight of mice in the Empty-LNP group and the vaccine group after challenge with vaccinia virus.
[0189] Figure 5 E: Survival rate of mice in the Empty-LNP group and the vaccine group after challenge with vaccinia virus.
[0190] ns or no mark: indicates no significant difference; * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001; **** indicates p<0.0001.
[0191] The weight changes and survival of mice in different groups were continuously observed. Figure 5 As shown in Figures B and 5C, compared with the VACV positive control group, the three mRNA vaccine groups were able to completely protect mice against infection with the lethal monkeypox virus; in terms of weight changes, the immune-enhancing fusion immunogen AMA-mIL-15 can promote the recovery of the weight of mice in the group more quickly. In terms of the protective effect against vaccinia virus, after a high dose of VACV virus, the protection efficiency of the multivalent mixed immunogen Mixture group was 75%, and the other two mRNA vaccine groups could provide complete protection, but the AMA-mIL-15 immunogen mRNA vaccine had a smaller weight change, which further illustrates that the addition of the immune-enhancing factor IL-15 also plays a key role in the clearance of the virus. These data provide preliminary evidence for the immune-enhancing fusion immunogen AMA-mIL-15mRNA vaccine group as a universal orthopoxvirus vaccine.
[0192] The procedure for the virus neutralization test (Focus reduction neutralization test, FRNT) of monkeypox virus and vaccinia virus is as follows.
[0193] a) Vero-E6 cells were inoculated into 96-well plates one day in advance, with 1.5×104 cells per well, and cultured overnight at 37°C, 5% CO2. The next day, the monkeypox virus neutralization experiment was brought into the BSL-3 laboratory, and the vaccinia virus neutralization experiment was brought into the BSL-2 laboratory.
[0194] b) On the day of the experiment, in a 96-well U-bottom dilution plate, plasma was diluted 4-fold or neutralizing antibodies were diluted 3-fold with maintenance medium, 6 or 9 concentration gradients, virus control (VC) and cell control (CC) were added with maintenance medium. 50 μL system, 10% complement of the total system concentration was added.
[0195] c) Take out the virus solution from the -80℃ freezer and thaw it at room temperature in a biosafety cabinet.
[0196] d) Dilute the thawed virus stock solution with an appropriate amount of maintenance culture medium (5 μL / 100 μL) and add equal volumes to the 96-well dilution plate containing the sample and the cell control with culture medium.
[0197] e) Place the dilution plate in a 37°C incubator and incubate for 1 hour.
[0198] f) Take a 96-well plate of Vero-E6 cells, discard the cell culture medium, add 50ul of sample-virus mixture to each well, and add 50uL of maintenance culture medium to the cell control well.
[0199] g) Place the 96-well cell plate in a 37°C incubator and incubate for 18 h.
[0200] h) After 18 hours, the Vero-E6 cells infected for 18 hours were taken out from the incubator, and the sample-virus mixture in the 96-well cell culture plate was discarded.
[0201] i) Add 200 μl of 4% paraformaldehyde to each well of the culture plate in a biosafety cabinet, then immerse the plate in 4% paraformaldehyde and fix at room temperature for 30 minutes before removing it from the laboratory.
[0202] j) Discard the paraformaldehyde, add 100 μl of 0.2% Triton X-100 to each well, and permeabilize the membrane for 10 minutes.
[0203] k) Discard 0.2% Triton X-100, add 200 μl PBS to each well, and let stand for 5 minutes.
[0204] l) Discard PBS, add 200 μl PBS to each well, and let stand in a biosafety cabinet for 5 minutes.
[0205] m) Discard PBS and add 50 μl of HRP-conjugated anti-VACV (Invitrogen) polyclonal antibody to each well.
[0206] n) After incubation at room temperature for 2 h, wash with PBS three times (same as step 15), and add 50 μl / well substrate for color development for 10 min.
[0207] o) Wash once with PBS (same as step 15), detect the number of spots by ELISpot scanner, calculate the neutralization inhibition rate, inhibition rate = [1-(average number of sample well spots-average number of cell control spots) / (average number of virus control spots-average number of cell control spots)] × 100%, and calculate ID50 using Graphpad Prism 9.0 software.
[0208] From the above embodiments, it can be seen that the monkeypox mRNA immunogen candidate AMA-mIL-15 for enhancing immune response provided by the present invention can simultaneously encode multiple protective epitope immunogens of MPXV from one mRNA molecule, achieve independent expression of each immunogen without mutual interference, and can not only quickly induce the body to produce an immune response, but also activate an effective cellular immune response, thereby better inhibiting viral replication, thereby providing a basic guarantee for responding to the current co-epidemic of monkeypox virus and HIV infection and the possibility of further widespread spread among the population.
[0209] The present invention provides an mRNA vaccine immunogen composition for anti-orthopoxvirus that can fuse and express the protective antigen protein of monkeypox virus and its homologous protein, and its application in the prevention and treatment of orthopoxvirus infection such as monkeypox virus and vaccinia virus. The composition is prepared by using an immunogen that can fuse and express various protective epitopes of monkeypox virus, and further improves the response intensity by adding cytokine IL-15 as an immunopotentiator. The composition can encode immunogens of multiple protective epitopes of MPXV from one mRNA molecule at the same time, and add secretory cytokines to achieve independent expression without mutual interference, thereby constructing an immune-enhancing multivalent fusion immunogen composition to prepare monkeypox mRNA vaccine, and one injection can effectively induce the body's immune response, and achieve complete protection against lethal doses of monkeypox virus and vaccinia virus.
[0210] The above description is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, any modifications, equivalent substitutions and improvements made within the spirit and principles of this application without departing from the principles of the present invention should be included in the protection scope of this application.
Claims
1. A monkeypox mRNA immunogen composition that rapidly and efficiently enhances immune response, characterized in that: The composition includes encoding at least one antigenic peptide or structural protein and the immune enhancing factor IL-15; The antigenic peptides or structural proteins are selected from: (1) the amino acid sequence of the full length or a portion of the monkeypox virus A35R protein, or an amino acid sequence that is at least 80% to 99% identical thereto and has the same or substantially the same immunogenicity; (2) the amino acid sequence of the entire length or a portion of the monkeypox virus M1R protein, or an amino acid sequence that is at least 80% to 99% identical thereto and has the same or substantially the same immunogenicity; (3) the amino acid sequence of the full length or a portion of the monkeypox virus A29L protein, or an amino acid sequence that is at least 80% to 99% identical thereto and has the same or substantially the same immunogenicity; The immune enhancing factor is selected from the amino acid sequence of the full length or part of the cytokine IL-15 of the gamma chain receptor cytokine family, or an amino acid sequence that has at least 80% to 99% identity thereto and has the same or substantially the same immunogenicity thereto; different candidate immunogenic molecules are arranged by a linker sequence.
2. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 1, characterized in that: The antigenic peptide or structural protein is selected from: (1) the amino acid sequence shown in SEQ ID NO: 1, (2) the amino acid sequence shown in SEQ ID NO: 2, and (3) the amino acid sequence shown in SEQ ID NO: 3; the antigenic peptide or structural protein includes a combination of two or more, which are expressed separately or fused.
3. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 1, characterized in that: The immune enhancing factor is selected from the amino acid sequence shown in SEQ ID NO:
4.
4. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 1, characterized in that: In the composition, the linker sequence is derived from the sequence of a self-cleaving peptide, including: linker 1 is a sequence derived from porcine teschovirus P2A; linker 2 is a sequence derived from the tricholoma punctatus virus T2A; linker 3 is a sequence derived from hand, foot and mouth disease virus F2A; the order between different linker sequences is arbitrary in front or behind.
5. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 4, characterized in that: In the linker sequence, linker 1 is the amino acid sequence ATNFSLLKQAGDVEENPGP as shown in SEQ ID NO:5, linker 2 is the amino acid sequence EGRGSLLTCGDVEENPGP as shown in SEQ ID NO:6, and linker 3 is the amino acid sequence GSGVKQTLNFDLLKLAGDVESNPGP as shown in SEQ ID NO:
7.
6. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 1, characterized in that: The composition is a monocistronic sequence arranged in series with a linker, which is loaded into the same mRNA expression vector, thereby achieving translation from the same transcript.
7. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to claim 6, characterized in that: The composition, in order to achieve efficient membrane display of each antigenic peptide or structural protein, replaces its own signal peptide with the secretory signal peptide tPA2 at its N-terminus, and further adds a Kozak sequence before the start codon to enhance expression; the Kozak sequence is shown in SEQ ID NO: 12; the amino acid sequence of the secretory signal peptide tPA2 is shown in SEQ ID NO: 13; the amino acid sequence of the final monkeypox virus fusion protein candidate immunogen 1 is shown in SEQ ID NO: 14, and the amino acid sequence of the monkeypox virus fusion protein candidate immunogen 2 is shown in SEQ ID NO: 15; the amino acid sequence of the immune-enhancing immunogen 1 is shown in SEQ ID NO: 16, and the amino acid sequence of the immune-enhancing immunogen 2 is shown in SEQ ID NO:
17.
8. The monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response according to any one of claims 1 to 7, characterized in that: The composition, whose nucleic acid sequence is optimized for codons and RNA secondary structure, includes: the full-length DNA sequence of the antigenic peptide or structural protein as shown in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or a sequence having at least 80% to 99% homology with the nucleic acid sequence shown therein; The coding codons and RNA secondary structure of candidate immunogens 1 and 2 encoding monkeypox virus fusion protein are optimized, and the optimized nucleic acid sequences are shown in SEQ ID NO: 21 and SEQ ID NO: 22, respectively; A cytokine IL-15 antigen sequence encoding codon optimization and RNA secondary structure optimization, wherein the codon-optimized nucleic acid sequence is shown in SEQ ID NO: 23; The nucleic acid sequences of the codon-optimized and RNA-secondary-structure-optimized immune-enhancing immunogens 1 and 2 are shown in SEQ ID NO: 24 and SEQ ID NO: 25, respectively; The fusion protein immunogen 1, fusion protein immunogen 2 and immune-enhancing immunogen composition 1, immune-enhancing immunogen composition 2 with optimized coding codons and optimized secondary structure loaded into the same mRNA vector, and their optimized DNA template sequences for mRNA preparations are shown as SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively.
9. A use of the monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response as claimed in claim 8, characterized in that: The composition is used to prepare an immune-enhancing monkeypox mRNA vaccine; the prepared vaccine comprises one or more pharmaceutically acceptable carriers or excipients of the monkeypox mRNA immunogen composition, and is suitable for oral, intradermal, subcutaneous, intramuscular or intranasal administration.
10. The use of the monkeypox mRNA immunogen composition for rapidly and efficiently enhancing immune response as claimed in claim 9, characterized in that: The vaccine is a multivalent fusion immune-enhancing monkeypox nucleic acid vaccine, and the administration methods include nasal drops and spray administration, subcutaneous injection, intradermal injection and intramuscular injection.
Citation Information
Cited By
Recombinant protein and application thereof in preparation of monkey pox vaccine
CN120365437A
Monkey pox virus vaccine based on chimpanzee adenovirus vector
CN121668295A
